Market Place
Sourcing Support
BioVaxys Partner SpayVac Scales Wildlife Vaccine Production
20 Nov 2024 //
PR NEWSWIRE
BioVaxys Joins BARDA Vaccine Development Consortium
05 Nov 2024 //
PR NEWSWIRE
BioVaxys` DPX Shows Superior Immune Activation in Study
31 Oct 2024 //
PR NEWSWIRE
BioVaxys Engages Dr. Rajagopalan As Vaccine Formulations Advisor
08 Oct 2024 //
PR NEWSWIRE
BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT
11 Sep 2024 //
PR NEWSWIRE
BioVaxys to Present DPX Immune Educating Platform Data at Cancer Vaccine Summit
04 Sep 2024 //
PR NEWSWIRE
BioVaxys DPX Vaccines Show Efficacy In Multiple Diseases
22 Aug 2024 //
PR NEWSWIRE
SPAYVAC Completes Research And Production Facility In Wisconsin
19 Aug 2024 //
PR NEWSWIRE
BioVaxys Partners to Develop DPX-Based Therapy for Food Allergies
29 Jul 2024 //
CONTRACT PHARMA
Biotheryx Doses First Patient In Phase 1 Trial Of CDK4/6 Degrader
17 Jul 2024 //
PR NEWSWIRE
BioVaxys Technology Corp. Announces Revocation of Cease Trade Order
11 Jul 2024 //
PR NEWSWIRE
Biovaxys Appoints Christopher Cherry as Chief Financial Officer
30 Apr 2024 //
PR NEWSWIRE
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
04 Apr 2024 //
PR NEWSWIRE
BioVaxys Allowance of formulation Patent for the US & Filing for Ph 1 SurMAGE
03 Apr 2024 //
PR NEWSWIRE
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
07 Mar 2024 //
PR NEWSWIRE
BioVaxys Announces Allowance of DPX-Related Patent for Japan
05 Mar 2024 //
PR NEWSWIRE
BioVaxys Acquires Intellectual Property of the Former IMV Inc.
12 Feb 2024 //
PR NEWSWIRE
BioVaxys executes LoI for major Immunotherapeutics technology acquisition
26 Dec 2023 //
INDIAN PHARMA POST
BioVaxys Executes Letter of Intent for Immunotherapeutics Technology Acquisition
22 Dec 2023 //
PR NEWSWIRE
BioVaxys in Non-Binding Discussions for Immunotherapeutics Acquisition
13 Dec 2023 //
PR NEWSWIRE
BIOVAXYS ANNOUNCES SALE OF TAET SOFTWARE CO
13 Jun 2023 //
PR NEWSWIRE
BIOVAXYS REPORTS AGM RESULTS
07 Jun 2023 //
PR NEWSWIRE
Biovaxys Announces Appointment Of Cfo And Board Changes
12 Apr 2023 //
PR NEWSWIRE
Biovaxys Acquires Study Management Company And Completes Private Placement
16 Mar 2023 //
PR NEWSWIRE
BioVaxys and Procare Health Execute US Distribution Agreement for Papilocare Gel
19 Dec 2022 //
PRNEWSWIRE
BioVaxys Co-Founder Kenneth Kovan to Present at Oncology Investor Conference
05 Dec 2022 //
PRNEWSWIRE
BioVaxys Announces Successful Test-Run Production of Ovarian Cancer Vaccine
01 Dec 2022 //
PRNEWSWIRE
BioVaxys Successfully Completes Sterile Test-Run for Ovarian Cancer Vax
01 Dec 2022 //
CONTRACTPHARMA
BioVaxys Sarbecovirus Vaccine Data Excellent Emerging Safety with BVX-1021
16 Nov 2022 //
PRNEWSWIRE
Biovaxys Announces Completed Private Placement And Debt Settlement
10 Nov 2022 //
PRNEWSWIRE
BioVaxys Executes Binding Term Sheet for US Marketing for Papilocare Gel
06 Oct 2022 //
PRNEWSWIRE
Biovaxys Announces Debt Settlement
06 Oct 2022 //
PRNEWSWIRE
Biovaxys Closes Final Tranche Of Non-Brokered Private Placement
19 Sep 2022 //
PRNEWSWIRE
BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate
06 Sep 2022 //
PRNEWSWIRE
BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT
04 Aug 2022 //
PRNEWSWIRE
Biovaxys Announces Proposed Debt Settlement
04 Jul 2022 //
PRNEWSWIRE
BioVaxys Confirms Ovarian Cancer Vaccine Trial; Enters Tumor Cell Supply Deal
18 May 2022 //
PRNEWSWIRE
International Patent Application Filed for Cervical Cancer Vaccine
02 May 2022 //
PRNEWSWIRE
BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess BVX-0918
25 Apr 2022 //
GLOBENEWSWIRE
BioVaxys Expands Cancer Vaccine Platform
30 Mar 2022 //
PRNEWSWIRE
BioVaxys says Bioproduction of BVX-1021 for its Pan-Sarbecovirus Program
17 Mar 2022 //
PRNEWSWIRE
Biovaxys: complete inhibition of ACE-2 receptor of haptenized SARS-CoV-2 protein
16 Feb 2022 //
PRNEWSWIRE
Biovaxys Announces Non-Brokered Private Placement
07 Feb 2022 //
PRNEWSWIRE
BioVaxys CMO, David Berd Invited by Editorial Board of Therapeutic Advances
18 Nov 2021 //
PRNEWSWIRE
BioVaxys Further Expands Intellectual Property Portfolio in Global Markets
28 Oct 2021 //
PRNEWSWIRE
BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine
20 Oct 2021 //
PRNEWSWIRE
BioVaxys Engages Life Sciences Public Relations & Market Communications Firm
20 Sep 2021 //
PRNEWSWIRE
BioVaxys` Partner Bio Elpida Reaches Bioproduction Milestone
17 Sep 2021 //
PRNEWSWIRE
BioVaxys Reports Progress on Covid-19 Vax Candidate
16 Sep 2021 //
CONTRACTPHARMA
WuXi Biologics completes protein synthesis of SARS-CoV-2 for BVX-0320 & CoviDTH
14 Sep 2021 //
PRNEWSWIRE
Clinical Trial Affirms CoviDTH Diagnostic Approach
03 Aug 2021 //
PRNEWSWIRE
FDA Provides BioVaxys to Begin Preparation of Indications for Phase I / II
23 Jul 2021 //
PRNEWSWIRE
FDA Provides BioVaxys to Begin Preparation of Indications for Phase I / II
23 Jul 2021 //
PRNEWSWIRE
FDA Provides BioVaxys to Begin Preparation of Indications for Phase I / II
23 Jul 2021 //
PRNEWSWIRE
Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor
24 May 2021 //
PRNEWSWIRE
Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor
24 May 2021 //
PRNEWSWIRE
BioVaxys Inks Deal with CDMO BioElpida
06 May 2021 //
CONTRACTPHARMA
BioVaxys And BioElpida Sign Definitive Exclusive Agreement
03 May 2021 //
PRNEWSWIRE
BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark App
29 Apr 2021 //
PRNEWSWIRE
BioVaxys Broadens Intellectual Property Portfolio Commercial Trademark
29 Apr 2021 //
PRNEWSWIRE
